Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Catalyst Pharmaceuticals fourth quarter and full year 2024 financial results conference call. At this time, all participants are on a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mike Cowan. Thank you, and you may begin. Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's fourth quarter and full year 2024 financial results and business highlights. Leading the call today is Richard Daley, Catalyst's President and Chief Executive Officer. We're also joined by Jeff Del Carmen, our Chief Commercial Officer. Further, for the Q&A session, Dr. Stephen Miller, our Chief Operating Officer and Chief Scientific Officer, and Dr. Gary Ingenito, our Chief Medical and Regulatory Officer, will be available for questions. Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of federal securities laws. These statements relate to our current expectations, estimates, and projections and are not guarantees of future performance. They involve risks, uncertainties, and assumptions that are difficult to predict and may prove not to be accurate. Actual results may vary from the expectations contained in our forward-looking statements. These forward-looking statements should be considered only in conjunction with the detailed information contained in our SEC filings, including the risk factors described in our 2024 Annual Report on Form 10-K. At...